HRP20221197T1 - Pripravak konjugata protuitijela i lijeka koji se može filtrirati a sadrži duokarmicin i srodne postupke - Google Patents
Pripravak konjugata protuitijela i lijeka koji se može filtrirati a sadrži duokarmicin i srodne postupke Download PDFInfo
- Publication number
- HRP20221197T1 HRP20221197T1 HRP20221197TT HRP20221197T HRP20221197T1 HR P20221197 T1 HRP20221197 T1 HR P20221197T1 HR P20221197T T HRP20221197T T HR P20221197TT HR P20221197 T HRP20221197 T HR P20221197T HR P20221197 T1 HRP20221197 T1 HR P20221197T1
- Authority
- HR
- Croatia
- Prior art keywords
- drug
- antibody
- duocarmycin
- linker
- preparation
- Prior art date
Links
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 title claims 15
- 229960005501 duocarmycin Drugs 0.000 title claims 15
- 229930184221 duocarmycin Natural products 0.000 title claims 15
- 239000000611 antibody drug conjugate Substances 0.000 title claims 12
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims 12
- 238000000034 method Methods 0.000 title claims 9
- 239000000203 mixture Substances 0.000 title claims 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 13
- 239000000706 filtrate Substances 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 5
- 238000001914 filtration Methods 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 239000004695 Polyether sulfone Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229920006393 polyether sulfone Polymers 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Pripravak, koji sadrži (a) sustav otapala koji sadrži vodu i acetonitril; (b) kiselinu; (c) konjugat protutijela-lijeka formule (I):
Ab-(L-D)m (I),
pri čemu je Ab protutijelo ili njegov fragment koji se veže na antigen, L-D poveznica-lijek duokarmicina i predstavlja prosječan DAR s od 1 do 12; i
izborno (d) poveznica-lijek duokarmicin u nekonjugiranom obliku;
pri čemu navedeni pripravak sadrži 30% do 60% (v/v), poželjno 35% do 55%, navedenog acetonitrila.
2. Pripravak sukladno patentnom zahtjevu 1, pri čemu navedeni pripravak nadalje sadrži navedeni poveznicu-lijek duokarmicin u nekonjugiranom obliku.
3. Pripravak sukladno patentnom zahtjevu 1 ili 2, pri čemu je navedeni konjugat protutijelo-lijek sadržan u koncentraciji od 0,1 do 100 mg/ml, poželjno od 0,5 do 50 mg/ml, još poželjnije od 1,0 do 10 mg/ml.
4. Pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 3 pri čemu je navedena kiselina sadržana u koncentraciji od 0,01% do 5% (v/v), poželjno od 0,05% do 2%, još poželjnije od 0,05% do 1,5%, najpoželjnije od 0,1% do 1%.
5. Pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je navedena kiselina odabrana između skupine koja sadrži trifluorooctenu kiselinu, mravlju kiselinu, i klorovodoničnu kiselinu.
6. Pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je navedena nekonjugirana poveznica-lijek duokarmicin predstavljena formulom (IV):
[image]
pri čemu je n 0-3; R5 je odabrano između
[image]
y je 1-16; i
R6 je odabrano između
[image]
7. Pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 6, pri čemu je navedena nekonjugirana poveznica-lijek duokarmicin predstavljena formulom
[image]
8. Pripravak sukladno bilo kojem od patentnih zahtjeva 1 do 7, pri je čemu navedeno protutijelo (Ab) IgG protutijelo ili njegov antigen vezujući fragment.
9. Postupak, koji sadrži kombiniranje (i) vodenaste otopine ili liofilizirani proizvod konjugata protutijela-lijeka formule (I):
Ab-(L-D)m (I),
pri je čemu Ab protutijelo ili njegov antigen vezujući fragment, L-D je poveznica-lijek duokarmicin i m predstavlja prosječan DAR s od 1 do 12, i izborno nadalje sadrži poveznicu-lijek duokarmicin u nekonjugiranom obliku, s (ii) podlogom otapala koji sadrži vodu, acetonitril, i kiselinu da bi se napravio pripravak, pri čemu navedeni pripravak sadrži 30% do 60% (v/v), poželjno 35% do 55%, navedenog acetonitrila.
10. Postupak sukladno patentnom zahtjevu 9, koji nadalje sadrži filtriranje opskrbljenog pripravka putem filtera koji sadrži odvajanje molekularne težine unutar obujma od 3 kDa do 50 kDa da bi se napravio filtrat koji je pretežno bez navedenog konjugata protutijela-lijeka, pri čemu se taj pojam "pretežito bez" odnosi na filtrat koji ne sadrži više od 1% količine navedenog konjugata protutijela-lijeka u navedenom pripravku.
11. Postupak sukladno patentnom zahtjevu 10, pri čemu je navedeno filtriranje centrifugalno filtriranje.
12. Postupak sukladno patentnom zahtjevu 11, pri čemu navedeni filter sadrži modificirani polietarsulfon.
13. Postupak sukladno bilo kojem od patentnih zahtjeva 10 do 12, koji nadalje sadrži podvrgavanje navedenog filtrata postupku kromatografskog odvajanja pogodnom za izoliranje navedene poveznice-lijeka duokarmicina u nekonjugiranom obliku i mjerenje količine, ukoliko postoji, navedena poveznica-lijek duokarmicina u nekonjugiranom obliku prisutnom u navedenom filtratu.
14. Postupak otpuštanja/odobravanja serije konjugata protutijela-lijeka, koji sadrži:
1) Dobivanje uzorka iz serije konjugata protutijela-lijeka, pri čemu navedena serija sadrži protutijelo konjugirano s poveznica-lijekom duokarmicinom i izborno poveznica-lijekom duokarmicinom u nekonjugiranom obliku;
2) Kombiniranje navedenog uzorka s podlogom otapanja koji sadrži vodu, acetonitril, i kiselinu da bi se napravio pripravak koji se može filtrirati koji sadrži 30% do 60% (v/v), poželjno 35% do 55%, navedenog acetonitrila;
3) Filtriranje navedenog pripravka koji može se filtrirati da bi se dobio filtrat koji je pretežito bez navedenog konjguata protutijela-lijeka, pri čemu se pojam "pretežito bez" odnosi na filtrat koji sadrži ne više od 1% količine navedenog konjugata protutijela-lijeka u navedenom pripravku koji se može filtrirati;
4) Analiziranje navedenog filtrata i određivanje da li navedeni filtrat sadrži navedenu poveznicu-lijek duokarmicin u nekonjugiranom obliku ispod unaprijed određene razine; i
5) Otpuštanje/odobravanje navedene serije konjugata protutijela-lijeka ako je navedena poveznica-lijek duokarmicin u nekonjugiranom obliku ispod navedene prethodno određene razine.
15. Postupak sukladno patentnom zahtjevu 14, pri čemu navedena prethodno određena razina odgovara koncentraciji poveznice-lijeka duokarmicina u tome uzorku koji je 0,2 µg/mg konjugata protutijelo-lijeka ili manje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18205459 | 2018-11-09 | ||
| EP19795572.7A EP3876997B1 (en) | 2018-11-09 | 2019-11-04 | Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods |
| PCT/EP2019/080084 WO2020094561A1 (en) | 2018-11-09 | 2019-11-04 | Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221197T1 true HRP20221197T1 (hr) | 2022-12-09 |
Family
ID=64270729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221197TT HRP20221197T1 (hr) | 2018-11-09 | 2019-11-04 | Pripravak konjugata protuitijela i lijeka koji se može filtrirati a sadrži duokarmicin i srodne postupke |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210386867A1 (hr) |
| EP (1) | EP3876997B1 (hr) |
| JP (1) | JP2022506860A (hr) |
| KR (1) | KR20210091752A (hr) |
| CN (1) | CN112969478B (hr) |
| AU (1) | AU2019376457A1 (hr) |
| BR (1) | BR112021008293A2 (hr) |
| CA (1) | CA3118788A1 (hr) |
| CL (1) | CL2021001199A1 (hr) |
| DK (1) | DK3876997T3 (hr) |
| ES (1) | ES2926980T3 (hr) |
| HR (1) | HRP20221197T1 (hr) |
| HU (1) | HUE059919T2 (hr) |
| IL (1) | IL282913B1 (hr) |
| LT (1) | LT3876997T (hr) |
| MX (1) | MX2021005484A (hr) |
| PL (1) | PL3876997T3 (hr) |
| PT (1) | PT3876997T (hr) |
| SG (1) | SG11202104413TA (hr) |
| WO (1) | WO2020094561A1 (hr) |
| ZA (1) | ZA202102798B (hr) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CN102317283A (zh) | 2008-11-03 | 2012-01-11 | 辛塔佳股份有限公司 | 新型cc-1065类似物及其缀合物 |
| MX336853B (es) | 2010-04-21 | 2016-01-19 | Syntarga Bv | Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales. |
| RU2016117810A (ru) * | 2013-10-11 | 2017-11-17 | Асана Биосайенсис, Ллк | Конъюгаты белок-полимер-лекарственное средство |
| CA2935077C (en) | 2013-12-27 | 2022-03-15 | Geoffrey C. Winters | Sulfonamide-containing linkage systems for drug conjugates |
| AU2015205509B2 (en) * | 2014-01-10 | 2019-08-15 | Byondis B.V. | Duocarmycin ADCs showing improved in vivo antitumor activity |
| US10407743B2 (en) | 2014-05-22 | 2019-09-10 | Synthon Biopharmaceuticals B.V. | Site-specific conjugation of linker drugs to antibodies and resulting ADCs |
| CN106458892B (zh) * | 2014-06-05 | 2019-10-18 | 斯索恩生物制药有限公司 | 用于制备倍癌霉素前药的改进方法 |
| AU2016292759B2 (en) * | 2015-07-10 | 2021-05-20 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
| ES2854298T3 (es) * | 2015-09-22 | 2021-09-21 | Byondis Bv | Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1 |
| JP6412906B2 (ja) * | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
-
2019
- 2019-11-04 MX MX2021005484A patent/MX2021005484A/es unknown
- 2019-11-04 BR BR112021008293-0A patent/BR112021008293A2/pt unknown
- 2019-11-04 LT LTEPPCT/EP2019/080084T patent/LT3876997T/lt unknown
- 2019-11-04 WO PCT/EP2019/080084 patent/WO2020094561A1/en unknown
- 2019-11-04 PL PL19795572.7T patent/PL3876997T3/pl unknown
- 2019-11-04 EP EP19795572.7A patent/EP3876997B1/en active Active
- 2019-11-04 HU HUE19795572A patent/HUE059919T2/hu unknown
- 2019-11-04 DK DK19795572.7T patent/DK3876997T3/da active
- 2019-11-04 KR KR1020217017573A patent/KR20210091752A/ko active Search and Examination
- 2019-11-04 US US17/291,141 patent/US20210386867A1/en active Pending
- 2019-11-04 ES ES19795572T patent/ES2926980T3/es active Active
- 2019-11-04 IL IL282913A patent/IL282913B1/en unknown
- 2019-11-04 CA CA3118788A patent/CA3118788A1/en active Pending
- 2019-11-04 HR HRP20221197TT patent/HRP20221197T1/hr unknown
- 2019-11-04 CN CN201980073803.0A patent/CN112969478B/zh active Active
- 2019-11-04 SG SG11202104413TA patent/SG11202104413TA/en unknown
- 2019-11-04 AU AU2019376457A patent/AU2019376457A1/en active Pending
- 2019-11-04 JP JP2021524477A patent/JP2022506860A/ja active Pending
- 2019-11-04 PT PT197955727T patent/PT3876997T/pt unknown
-
2021
- 2021-04-26 ZA ZA2021/02798A patent/ZA202102798B/en unknown
- 2021-05-06 CL CL2021001199A patent/CL2021001199A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210386867A1 (en) | 2021-12-16 |
| JP2022506860A (ja) | 2022-01-17 |
| ZA202102798B (en) | 2022-08-31 |
| SG11202104413TA (en) | 2021-05-28 |
| PL3876997T3 (pl) | 2022-12-19 |
| CN112969478A (zh) | 2021-06-15 |
| KR20210091752A (ko) | 2021-07-22 |
| CA3118788A1 (en) | 2020-05-14 |
| AU2019376457A1 (en) | 2021-05-27 |
| HUE059919T2 (hu) | 2023-01-28 |
| WO2020094561A1 (en) | 2020-05-14 |
| BR112021008293A2 (pt) | 2021-08-03 |
| MX2021005484A (es) | 2021-06-18 |
| EP3876997A1 (en) | 2021-09-15 |
| IL282913A (en) | 2021-06-30 |
| ES2926980T3 (es) | 2022-10-31 |
| LT3876997T (lt) | 2022-11-10 |
| CL2021001199A1 (es) | 2021-12-17 |
| DK3876997T3 (da) | 2022-09-26 |
| CN112969478B (zh) | 2023-10-27 |
| IL282913B1 (en) | 2024-03-01 |
| PT3876997T (pt) | 2022-11-11 |
| EP3876997B1 (en) | 2022-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6947630B2 (ja) | 生物学的物質及びその使用 | |
| DE69835201T2 (de) | Neoglycoproteine | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| KR20150032716A (ko) | 항cd70 항체 약물 컨쥬게이트 | |
| JP2020109162A (ja) | ポリマー色素修飾および適用 | |
| CN105813655A (zh) | 蛋白-聚合物-药物缀合物 | |
| CN103648530A (zh) | 蛋白质-活性剂缀合物及其制备方法 | |
| JP2016512540A5 (hr) | ||
| CN107043406B (zh) | 化合物、连接子-药物、及配体-药物耦合体 | |
| CN103732595A (zh) | 叶酸的白蛋白-结合实体缀合物 | |
| CN106922129A (zh) | 轭合多肽的方法 | |
| CN107496933A (zh) | 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法 | |
| RU2762594C2 (ru) | Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения | |
| CN106866822A (zh) | 半胱氨酸改造的抗体‑毒素偶联物 | |
| JP3372551B2 (ja) | 多価ポリマー、その製造方法、および生物学的に活性な化合物の製造におけるその使用 | |
| JP2020525441A (ja) | 薬物担持ポリマースキャフォールドおよびタンパク質−ポリマー−薬物コンジュゲートを製造する方法 | |
| CN110650947A (zh) | 方法和分子 | |
| JP2022511219A (ja) | 抗Ｈｅｒ２抗体薬物コンジュゲートの製剤 | |
| HRP20221197T1 (hr) | Pripravak konjugata protuitijela i lijeka koji se može filtrirati a sadrži duokarmicin i srodne postupke | |
| JP2022515884A (ja) | 切断可能なリンカーを含む化合物及びその使用 | |
| AU2021207461A1 (en) | Anti-Gal3 antibodies and methods of use | |
| CN107106702A (zh) | 使用亲和树脂合成adc的方法 | |
| Tappertzhofen et al. | Synthesis of Maleimide‐Functionalyzed HPMA‐Copolymers and in vitro Characterization of the aRAGE‐and Human Immunoglobulin (huIgG)–Polymer Conjugates | |
| EP3770170A1 (en) | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc) | |
| RU2774642C1 (ru) | Фильтруемые композиции дуокармицин-содержащих конъюгатов антитело-лекарственное средство и связанные с ними способы |